🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-526282-25-00
Authorised Phase I

A Phase 1b Basket Study Evaluating B Cell Depletion in Blood and Tissue by Etentamig or ABBV-519 in Subjects with Moderate to Severe Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), or Sjögren's Disease (SjD)

2026-526282-25-00 · tracked via the Priya Life Science EU tracker
Sponsor
AbbVie Deutschland GmbH & Co. KG
Sponsor type
Pharmaceutical company
Therapeutic area
Immune System Diseases
Decision date
10/09/2026
Enrollment target
20
Sites
Germany

Condition studied

Systemic lupus erythematosus, sjögren's disease and rheumatoid arthritis

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-526282-25-00 on CTIS ↗ ← All trials in the EU